[Paget's disease of bone].
Shinjiro Takata
Abstract
Shinjiro Takata
Abstract
Paget's disease of bone (PDB) is a chronic disorder characterized by focal abnormalities of bone turnover. The symptoms of PDB include bone pain, bone deformity, osteoarthritis, and an increase in risk of pathological fracture and neurological problems. PDB is the second most common metabolic bone disease in European countries, although PDB is uncommon in Japan. PDB shows geographical and ethnic clustering. Based on this, two hypotheses of etiology of PDB have been proposed. One hypothesis is that PDB results from a slow virus infection of osteoclasts with paramyxovirus. The other is that PDB is a genetic disease. The development of bisphosphonate has brought major changes to the treatment of PDB. In Japan, etidronate and calcitonin are approved by the Ministry of Health, Labour and Welfare for treating PDB. Risedronate is under development for treating PDB in Japan.
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Paget's disease of bone (PDB) is a chronic disorder characterized by focal abnormalities of bone turnover. The symptoms of PDB include bone pain, bone deformity, osteoarthritis, and an increase in risk of pathological fracture and neurological problems. PDB is the second most common metabolic bone disease in European countries, although PDB is uncommon in Japan. PDB shows geographical and ethnic clustering. Based on this, two hypotheses of etiology of PDB have been proposed. One hypothesis is that PDB results from a slow virus infection of osteoclasts with paramyxovirus. The other is that PDB is a genetic disease. The development of bisphosphonate has brought major changes to the treatment of PDB. In Japan, etidronate and calcitonin are approved by the Ministry of Health, Labour and Welfare for treating PDB. Risedronate is under development for treating PDB in Japan.
Key concepts: Protein Data Bank (RCSB PDB), Paget's disease of bone, Medicine, Bone remodeling, Protein Data Bank, Etiology, Bone pain, Bioinformatics